Dear Reader,

In our current issue, we are pleased to present a series of papers related to ***Influenza Vaccines***. The bioinformatics analysis of H7N9 protein sequences and comparison of their T-cell epitope content to other circulating influenza A strains predict that a conventional vaccine for this strain will be weakly immunogenic such that novel strategies for improving vaccine immunogenicity will be needed (De Groot, p. 950). Other papers in this section include studies of cellular immune responses to a H1N1 vaccine in HIV-infected children (Weinberg, p. 957), and the impact of vitamin D administration on immunogenicity of influenza vaccine (Principi, p. 969). Related to the latter paper, we publish two Letters to the Editor on vitamin D and influenza vaccination (Wiwanitkit, p. 975; and Principi, p. 976). This section also contains a review on the controversy over H5N1 transmissibility research (Fedson, p. 977), a case-cohort study on seasonal influenza vaccine effectiveness in children (Fu, p. 987), and a case report of a patient with cross-reactive antibodies against pandemic 2009 H1N1 virus in a sample from 1999 (Yoshida, p. 989).

Several papers in this issue are related to the topic of ***Immunotherapy***: HDAC inhibitors against latent HIV infection (Rasmussen, p. 993), a DN- based Alzheimers' disease epitope vaccine (Ghochikyan, p. 1002), the role of HIV-specific ADCC antibodies in protective immunity (Madhavi, p. 1011), and the development of a DNA and protein mixture vaccine for treating cat allergy (Pei, p. 1019). Two commentaries discuss tolerogenic vaccines for Multiple Sclerosis (Mannie, p. 1032), and oral passive IgY-based immunotherapeutics for preventing and treating alimentary tract diseases (Rahman, p. 1039).

The section on *Cancer* features a study on clinical evaluation of therapeutic cancer vaccines (Ogi, p. 1049), a review on the listeriolysin O molecule for development of new anti-tumor vaccines (Sun, p. 1058), and three commentaries discussing immunotherapy for treatment of biliary tract cancer (Takahashi, p. 1069), the use of universal tumor-reactive peptides derived from telomerase for CD4^+^ T cell-based immunotherapy (Adotévi, p. 1073), and idiotypic vaccination for B-cell non-Hodgkin lymphomas (Muraro, p. 1078).

Three research papers and one commentary fall in the category ***Novel Vaccines***: preclinical testing of flagellin as a potential mucosal adjuvant (Yang, p. 1084), evaluation of pro-inflammatory responses after DNA therapy of tuberculosis (Zárate-Bladés, p. 1093), development of a recombinant pre-erythrocytic stage DNA vaccine against malaria (Zhao, p. 1104), and prophylactic VLP-based HCV vaccines (Beaumont, p. 1112).

Studies on ***Health Economics*** look at the first 20 years of universal HBV vaccination program in Italy (Boccalini, p. 1119), cost-effectiveness of meningococcal B vaccination of Dutch infants (Pouwels, p. 1129), and the economics of vaccines (Postma, p. 1139).

Two papers are related to ***Public Programs***: successful implementation of pertussis cocooning in Italy (Simonetti, p. 1142), and the comparison of three HPV vaccination strategies for females in a low-resource setting (Small, p. 1146).

Vaccine ***Safety*** is the general theme of a short report on the association between socioeconomic status and adverse events following immunization of infants (Wilson, p. 1153), and a review on vaccine administration and the development of immune thrombocytopenic purpura in children (Cecinati, p. 1158).

Finally, the section on ***Licensed Vaccines*** features a review on epidemiology of vaccines against tick-borne encephalitis (TBE) in Europe (Amicizia, p.1163), a short report on the effectiveness of one and two doses of varicella vaccine in children in Spain (García Cenoz, p. 1172), and a commentary on vaccination against herpes zoster (Drolet, p. 1177).

We are pleased to present the portrait of Dr Dan Granoff in this issue. Dr Granoff is Director of the Center for Immunobiology and Vaccine Development at the Children's Hospital Oakland Research Institute (CHORI) in Oakland (CA, USA). Read his essay to learn about his role in the development and implementation of the Hib vaccine in the 1980s, as well as the low-cost serogroup A meningococcal conjugate vaccine for Africa in 2010.

In our monthly News, Policy & Profiles (NP&P) section we offer a selection of the latest news in the field of vaccines and immunotherapeutics. Our NP&P track is an excellent platform to share your opinion on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. It is also a good place to present your company or organization to an interested specialist audience. Please contact the Acquisitions Editor Eva Riedmann (eva\@landesbioscience.com) with your ideas for a commentary or if you would like to see your company/organization featured in a future issue of *HV&I*.

Finally, we want to draw your attention to several popular web site features, including an iPad application that allows you to read the full issue of *HV&I* anywhere, just as you would the print issue, an RSS feed to see the latest published papers, and a *HV&I*facebook account for daily updates.

Sincerely,

Ronald Ellis PhD

Editor-in-Chief

Eva M. Riedmann PhD

Acquisitions Editor
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